She had been diagnosed as having metastatic pulmonary neuroendocrine tumor. The patient's medical and family history was unremarkable; she had, however, smoked more than 20 cigarettes per day for ...

The new trial, headed by Aman Chauhan, M.D., leader of the Neuroendocrine Tumor Program at Sylvester, offers a fresh approach. Patients will receive a combination of immunotherapy drugs and a ...

SCLC patients, particularly with high tumor burden, face significant ATLS risk, despite typically low overall risk in solid tumors. Early recognition and aggressive intervention are crucial ...

Despite promising results, LTF is not the sole predictor of treatment response, and tumor burden may still influence outcomes in ES-SCLC patients. In a small study, lactotransferrin (LTF ...

“At just 40% of the administered dose reported for Ac-DOTATATE, Ac-EBTATE produces enhanced anti-tumor efficacy in small cell lung cancer (SCLC) and Pan-neuroendocrine tumor (NET) models as ...

The FDA has approved Cabometyx for some patients 12 years old and older with pancreatic neuroendocrine tumors and extra-pancreatic neuroendocrine tumors. 177Lu-edotreotide shows potential to extend ...

Imdelltra becomes the first DLL3-targeting BiTE therapy that activates the patient's own T cells to attack DLL3-expressing tumor cells. DLL3 is a protein that is expressed on the surface of SCLC ...

In a series of experiments, Auron showed that treatment with AUTX-703 potently degraded KAT2A/B, inhibited tumor growth, and induced durable cell state differentiation across models of SCLC.

A phase 1 clinical trial is now open for enrollment to patients with high-grade neuroendocrine tumors to receive treatment with a combination of immunotherapy and what has been described in a news ...